Nexpring Health

Nexpring is a clinical-stage biotechnology company based in Seoul, South Korea, dedicated to the discovery and development of novel small molecule therapeutics for chronic inflammatory and fibrotic diseases. The company's lead program, NX-1607, is a selective agonist of G protein-coupled receptor 120 (GPR120), also known as FFAR4, which is currently in Phase 1 clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Nexpring leverages its deep expertise in GPCR signaling and metabolic pathways to address high unmet medical needs in hepatology and nephrology. Founded by experienced leaders from the pharmaceutical industry, the company aims to provide first-in-class or best-in-class treatments for complex metabolic disorders. Its pipeline also includes early-stage programs targeting various fibrotic conditions and metabolic syndromes.